Azurity Archives
News and events as they happenAzurity Pharmaceuticals Expands Portfolio with CONTRAVE® and Related Assets
WOBURN, Mass. — June 30, 2026 — Azurity Pharmaceuticals, a global pharmaceutical company dedicated to redefining medicine for the real world, today announced the expansion of its portfolio through the acquisition of CONTRAVE® and related assets, expanding the company’s presence in obesity and chronic weight management.
Azurity Pharmaceuticals Announces FDA Approval of Aprepitant Injectable Emulsion, Expanding Access to Critical Supportive Oncology Care
WOBURN, MA – June 25, 2026 – Azurity Pharmaceuticals, a global pharmaceutical company dedicated to redefining medicine for the real world, today announced that the U.S. Food and Drug Administration (FDA) has approved Aprepitant Injectable Emulsion, a practical, administration-friendly treatment option aimed at making the patient experience more manageable.
ACA Pharma and Azurity Pharmaceuticals Announce Approval of Feraheme® and Ferabright™ in Macau
NEW YORK, NY May 21, 2026 — ACA Pharma and Azurity Pharmaceuticals announced that Feraheme® and Ferabright™ have each received regulatory approval in Macau, marking an important step in expanding access to ferumoxytol-based products across key markets in Asia. These approvals reflect the continued collaboration between ACA Pharma and Azurity to advance regulatory pathways and improve patient access throughout Greater China.
Azurity Pharmaceuticals Announces the Availability of ARYNTATM (lisdexamfetamine dimesylate) Oral Solution, CII
Woburn, MA — April 6, 2026 — Azurity Pharmaceuticals, Inc. announced that ARYNTATM (lisdexamfetamine dimesylate) Oral Solution is now available in the United States for treating ADHD in adults and pediatric patients 6 years and older. Arynta, a ready-to-use lisdexamfetamine oral solution that may be stored at room temperature between 68°F to 77°F (20°C to 25°C),1 received FDA approval in June 2025.
